These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

529 related articles for article (PubMed ID: 1724640)

  • 21. Bisphosphonates: an overview with special reference to alendronate.
    Vasikaran SD
    Ann Clin Biochem; 2001 Nov; 38(Pt 6):608-23. PubMed ID: 11732644
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Bisphosphonates: mode of action and pharmacology.
    Russell RG
    Pediatrics; 2007 Mar; 119 Suppl 2():S150-62. PubMed ID: 17332236
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Bisphosphonates: from grandparents to grandchildren.
    Srivastava T; Alon US
    Clin Pediatr (Phila); 1999 Dec; 38(12):687-702. PubMed ID: 10618761
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Treatment of tumor-induced osteolysis by APD.
    Burckhardt P; Thiébaud D; Perey L; von Fliedner V
    Recent Results Cancer Res; 1989; 116():54-66. PubMed ID: 2762665
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Ibandronate, an experimental intravenous bisphosphonate for osteoporosis, bone metastases, and hypercalcemia of malignancy.
    Guay DR
    Pharmacotherapy; 2006 May; 26(5):655-73. PubMed ID: 16637795
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Bisphosphonates, specific inhibitors of osteoclast function and a class of drugs for osteoporosis therapy.
    Li B; Ling Chau JF; Wang X; Leong WF
    J Cell Biochem; 2011 May; 112(5):1229-42. PubMed ID: 21465521
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Rationale for the use of bisphosphonates in bone metastases.
    Kanis JA; McCloskey EV; Taube T; O'Rourke N
    Bone; 1991; 12 Suppl 1():S13-8. PubMed ID: 1954047
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Comparative tolerability of drug therapies for hypercalcaemia of malignancy.
    Zojer N; Keck AV; Pecherstorfer M
    Drug Saf; 1999 Nov; 21(5):389-406. PubMed ID: 10554053
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Biphosphonate therapy in the management of skeletal metastases].
    Grauer A; Ziegler R
    Orthopade; 1998 Apr; 27(4):231-9. PubMed ID: 9616882
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Bisphosphonates in malignant hypercalcemia and bone pain].
    Lamy O
    Rev Med Suisse Romande; 2004 Feb; 124(2):111-4. PubMed ID: 15095627
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Etidronic acid. A review of its pharmacological properties and therapeutic efficacy in resorptive bone disease.
    Dunn CJ; Fitton A; Sorkin EM
    Drugs Aging; 1994 Dec; 5(6):446-74. PubMed ID: 7858370
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Treatment of tumour-induced hypercalcaemia with the bisphosphonate pamidronate: dose-response relationship and influence of tumour type.
    Body JJ; Dumon JC
    Ann Oncol; 1994 Apr; 5(4):359-63. PubMed ID: 8075034
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Bisphosphonates: biological response modifiers in breast cancer.
    Paterson AH
    Clin Breast Cancer; 2002 Aug; 3(3):206-16; discussion 217-8. PubMed ID: 12196279
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Bisphosphonate treatment of bone metastases and hypercalcemia of malignancy.
    Coleman RE
    Oncology (Williston Park); 1991 Aug; 5(8):55-60; discussion 60-2, 65. PubMed ID: 1834153
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Diphosphonates in the treatment of hypercalcemia].
    Delmas PD; Meunier PJ
    Rev Med Interne; 1984 Nov; 5(4):363-6. PubMed ID: 6240753
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Therapy insight: the risks and benefits of bisphosphonates for the treatment of tumor-induced bone disease.
    Dunstan CR; Felsenberg D; Seibel MJ
    Nat Clin Pract Oncol; 2007 Jan; 4(1):42-55. PubMed ID: 17183355
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Current use of bisphosphonates in oncology. International Bone and Cancer Study Group.
    Body JJ; Bartl R; Burckhardt P; Delmas PD; Diel IJ; Fleisch H; Kanis JA; Kyle RA; Mundy GR; Paterson AH; Rubens RD
    J Clin Oncol; 1998 Dec; 16(12):3890-9. PubMed ID: 9850035
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The pharmacology of bisphosphonates and new insights into their mechanisms of action.
    Russell RG; Rogers MJ; Frith JC; Luckman SP; Coxon FP; Benford HL; Croucher PI; Shipman C; Fleisch HA
    J Bone Miner Res; 1999 Oct; 14 Suppl 2():53-65. PubMed ID: 10510215
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Bisphosphonates for cancer patients: why, how, and when?
    Body JJ; Mancini I
    Support Care Cancer; 2002 Jul; 10(5):399-407. PubMed ID: 12136223
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Advances in the biology and treatment of myeloma bone disease.
    Berenson JR
    Am J Health Syst Pharm; 2001 Nov; 58 Suppl 3():S16-20. PubMed ID: 11757204
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 27.